

Supplement Table S1. Indices for organism's status measured in control (sham-exposed) and exposed to NiO-NP rats ($x \pm s.e.$)

Indices	Duration of Exposure							
	2 weeks		4 weeks		3 Months		6 Months	
	Contro l	NiO- NP	Contro l	NiO- NP	Contro l	NiO- NP	Contro l	NiO- NP
Body mass before exposure, g	230.00 ± 4.48	231.25 ± 5.05	228.14 ± 3.86	222.43 ± 4.68	272.00 ± 5.04	261.29 ± 6.92	272.54 ± 9.13	260.50 ± 8.62
Body mass after exposure, g	242.00 ± 3.49	233.25 ± 4.87	246.29 ± 3.15	241.21 ± 4.35	273.36 ± 6.56	263.57 ± 7.36	288.46 ± 10.23	280.71 ± 9.29
Body mass gain, %	5.49 \pm 1.04	0.95 \pm 0.79 *	8.06 \pm 0.61	8.59 \pm 1.01	0.50 \pm 1.58	0.96 \pm 1.60	6.36 \pm 3.22	8.11 \pm 2.22
Number of head-dips into holes during 3 min	5.20 \pm 0.51	5.50 \pm 0.52	8.07 \pm 1.21	8.79 \pm 1.01	7.00 \pm 1.10	6.71 \pm 0.87	5.38 \pm 0.93	6.07 \pm 0.79
Number of crossed squares per 3 min	10.85 \pm 1.13	10.35 \pm 0.94	15.71 \pm 1.69	18.14 \pm 1.80	12.93 \pm 1.57	14.29 \pm 1.68	11.38 \pm 1.40	12.79 \pm 1.22
Total number of movements on the "open field" during 3 min	19.05 \pm 1.78	19.15 \pm 1.73	27.93 \pm 3.08	32.79 \pm 3.59	24.86 \pm 2.65	26.36 \pm 3.12	20.77 \pm 2.38	22.36 \pm 1.96
Temporal summation of sub-threshold impulses, sec	17.80 \pm 0.44	16.07 \pm 0.48 *	13.18 \pm 0.53	11.82 \pm 0.53	8.32 \pm 1.13	8.46 \pm 0.69	9.45 \pm 0.99	11.56 \pm 0.84
Brain mass, g	1.91 \pm 0.04	1.94 \pm 0.03	1.96 \pm 0.06	1.86 \pm 0.06	2.03 \pm 0.03	1.95 \pm 0.03	2.07 \pm 0.05	1.89 \pm 0.06 *
Heart mass, g	0.75 \pm 0.02	0.79 \pm 0.03	0.83 \pm 0.02	0.77 \pm 0.02	0.92 \pm 0.03	0.90 \pm 0.03	1.09 \pm 0.03	1.02 \pm 0.06
Liver mass, g	7.10 \pm 0.19	7.13 \pm 0.26	9.09 \pm 0.12	8.93 \pm 0.31	9.17 \pm 0.74	9.28 \pm 0.42	10.22 \pm 0.69	9.70 \pm 0.65
Spleen mass, g	0.45 \pm 0.02	0.47 \pm 0.02	0.56 \pm 0.03	0.50 \pm 0.02	0.57 \pm 0.03	0.50 \pm 0.02	0.66 \pm 0.03	0.57 \pm 0.03
Kidney mass, g	1.43 \pm 0.03	1.37 \pm 0.07	1.56 \pm 0.03	1.47 \pm 0.05	1.91 \pm 0.09	1.76 \pm 0.06	2.15 \pm 0.06	1.95 \pm 0.06 *
Lung mass, g	1.28 \pm 0.06	1.33 \pm 0.06	2.07 \pm 0.28	1.88 \pm 0.19	2.32 \pm 0.31	2.41 \pm 0.31	2.50 \pm 0.33	2.77 \pm 0.66
Brain mass, g per 100 g body mass	0.81 \pm 0.02	0.86 \pm 0.03	0.81 \pm 0.03	0.76 \pm 0.03	0.75 \pm 0.03	0.75 \pm 0.03	0.71 \pm 0.04	0.68 \pm 0.03
Heart mass, g per 100 g body mass	0.33 \pm 0.01	0.33 \pm 0.02	0.34 \pm 0.01	0.32 \pm 0.01	0.34 \pm 0.01	0.34 \pm 0.01	0.37 \pm 0.02	0.36 \pm 0.02

Indices	Duration of Exposure							
	2 weeks		4 weeks		3 Months		6 Months	
	Contro l	NiO- NP	Contro l	NiO- NP	Contro l	NiO- NP	Contro l	NiO- NP
Liver mass, g per 100 g body mass	3.14 ± 0.14	3.01 ± 0.10	3.74 ± 0.08	3.66 ± 0.15	3.33 ± 0.21	3.56 ± 0.18	3.41 ± 0.16	3.42 ± 0.18
Spleen mass, g per 100 g body mass	0.20 ± 0.01	0.20 ± 0.01	0.23 ± 0.01	0.20 ± 0.01	0.21 ± 0.01	0.19 ± 0.01 *	0.22 ± 0.01	0.20 ± 0.01
Kidney mass, g per 100 g body mass	0.60 ± 0.01	0.60 ± 0.02	0.64 ± 0.01	0.60 ± 0.02	0.70 ± 0.03	0.67 ± 0.03	0.73 ± 0.02	0.69 ± 0.02
Lung mass, g per 100 g body mass	0.54 ± 0.02	0.59 ± 0.03	0.85 ± 0.11	0.76 ± 0.06	0.85 ± 0.10	0.93 ± 0.13	0.86 ± 0.13	1.02 ± 0.28
Hemoglobin, g/dL	148.80 ± 3.57	156.60 ± 6.55	154.00 ± 2.78	148.67 ± 2.76	150.86 ± 2.92	156.57 ± 6.00	176.33 ± 12.37	169.14 ± 7.42
Hematocrit, %	22.74 ± 0.54	24.22 ± 1.01	19.80 ± 0.72	19.28 ± 0.61	20.81 ± 0.63	21.49 ± 0.74	24.52 ± 1.96	24.06 ± 1.12
Reticulocytes, ‰	5.10 ± 0.64	7.10 ± 0.46 *	7.67 ± 1.41	11.67 ± 1.67	-	-	6.17 ± 0.31	16.14 ± 1.40 *
Erythrocytes, 10 ¹² cells/L	7.41 ± 0.17	7.82 ± 0.33	7.54 ± 0.18	7.44 ± 0.13	7.05 ± 0.19	7.32 ± 0.22	8.75 ± 0.80	8.44 ± 0.41
Mean corpuscular volume, µm ³ .	61.42 ± 0.67	61.97 ± 0.72	52.47 ± 0.78	51.80 ± 0.89	59.04 ± 0.96	58.71 ± 1.25	57.17 ± 0.90	57.13 ± 0.82
Mean corpuscular hemoglobin, 10 ⁻¹² g	20.10 ± 0.19	20.03 ± 0.23	20.47 ± 0.25	19.97 ± 0.24	21.43 ± 0.23	21.03 ± 0.31	20.63 ± 0.29	20.10 ± 0.40
Mean corpuscular hemoglobin concentration, g/L	327.20 ± 2.43	323.20 ± 1.25	390.50 ± 9.40	386.50 ± 8.62	363.14 ± 5.18	358.86 ± 5.79	344.83 ± 19.20	351.86 ± 4.76
Red cell distribution width, %	13.24 ± 0.20	12.97 ± 0.24	11.47 ± 0.20	11.17 ± 0.33	13.33 ± 0.29	12.97 ± 0.17	12.38 ± 0.33	11.97 ± 0.24
Thrombocytes, 10 ³ /µL	821.60 ± 60.92	823.00 ± 51.90	718.00 ± 34.25	635.33 ± 68.61	706.57 ± 17.88	811.43 ± 45.83	729.00 ± 80.13	814.57 ± 41.19
Mean platelet volume, µm ³	5.50 ± 0.08	5.54 ± 0.07	5.37 ± 0.07	5.55 ± 0.11	6.00 ± 0.14	5.61 ± 0.08	5.83 ± 0.09	5.66 ± 0.08
Thrombocrit, %	0.22 ± 0.02	0.23 ± 0.01	0.19 ± 0.01	0.18 ± 0.02	0.21 ± 0.01	0.23 ± 0.01	0.21 ± 0.02	0.23 ± 0.01
Thrombocyte distribution width, %	12.71 ± 0.51	12.90 ± 0.24	12.45 ± 0.36	13.23 ± 0.21	13.59 ± 0.49	13.80 ± 0.57	14.33 ± 0.32	14.60 ± 0.78
Leukocytes, 10 ³ /µL	5.64 ± 0.72	6.66 ± 0.63	6.30 ± 0.43	6.43 ± 0.17	7.03 ± 0.59	6.71 ± 1.20	7.93 ± 0.63	7.59 ± 0.74

Indices	Duration of Exposure							
	2 weeks		4 weeks		3 Months		6 Months	
	Contro 1	NiO- NP	Contro 1	NiO- NP	Contro 1	NiO- NP	Contro 1	NiO- NP
Basophils, 10 ³ /μL	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Eosinophils, 10 ³ /μL	0.21 ± 0.03	0.44 ± 0.11	0.20 ± 0.04	0.26 ± 0.06	0.40 ± 0.06	0.23 ± 0.06	0.43 ± 0.08	0.47 ± 0.08
Banded neutrophils, 10 ³ /μL	0.06 ± 0.01	0.08 ± 0.01	0.07 ± 0.01	0.06 ± 0.00	0.07 ± 0.01	0.07 ± 0.01	0.10 ± 0.02	0.08 ± 0.01
Segmented neutrophils, 10 ³ /μL	1.10 ± 0.13	1.26 ± 0.13	1.36 ± 0.13	1.29 ± 0.07	1.80 ± 0.22	1.59 ± 0.32	0.10 ± 0.02	0.08 ± 0.01
Monocytes, 10 ³ /μL	0.30 ± 0.03	0.35 ± 0.03	0.32 ± 0.03	0.34 ± 0.01	0.39 ± 0.06	0.45 ± 0.09	1.78 ± 0.17	1.76 ± 0.20
Lymphocytes, 10 ³ /μL	3.97 ± 0.55	4.52 ± 0.42	4.35 ± 0.31	4.47 ± 0.23	4.37 ± 0.32	4.38 ± 0.74	5.18 ± 0.50	4.84 ± 0.46
Basophils, %	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Eosinophils, %	4.00 ± 0.52	6.00 ± 1.01	3.33 ± 0.61	4.17 ± 1.05	5.71 ± 0.92	3.14 ± 0.51	5.67 ± 1.20	5.57 ± 0.69
Banded neutrophils, %	1.00 ± 0.00	1.20 ± 0.20	1.17 ± 0.17	1.00 ± 0.00	1.00 ± 0.00	1.14 ± 0.14	1.33 ± 0.33	1.00 ± 0.00
Segmented neutrophils, %	20.20 ± 1.23	19.10 ± 1.22	21.50 ± 0.85	20.17 ± 1.25	25.29 ± 1.32	23.00 ± 1.54	22.50 ± 1.36	23.00 ± 0.53
Monocytes, %	5.50 ± 0.31	5.40 ± 0.27	5.00 ± 0.37	5.33 ± 0.21	5.43 ± 0.48	6.57 ± 0.57	5.50 ± 0.22	6.00 ± 0.38
Lymphocytes, %	69.30 ± 1.54	68.30 ± 1.65	69.00 ± 1.21	69.33 ± 2.29	62.57 ± 1.46	66.14 ± 2.10	65.00 ± 2.13	64.00 ± 0.90
Succinate dehydrogenase (SDH) activity, number of formazan granules per 50 lymphocytes	587.00 ± 14.30	618.70 ± 18.01	560.67 ± 5.48	558.00 ± 8.53	582.29 ± 7.39	571.14 ± 6.05	526.67 ± 7.79	519.14 ± 5.54
Total protein content of blood serum, g/L	77.63 ± 1.71	77.05 ± 1.30	77.57 ± 0.73	77.25 ± 0.67	71.70 ± 1.53	70.29 ± 1.28	79.13 ± 1.96	80.46 ± 1.04
Albumin content of blood serum, g/L	45.97 ± 0.53	45.62 ± 0.34	47.72 ± 0.80	46.72 ± 0.92	41.30 ± 0.53	40.19 ± 2.10	43.72 ± 2.20	44.07 ± 1.58
Globulins of blood serum, g/L	31.67 ± 1.44	31.43 ± 1.07	29.85 ± 0.74	30.53 ± 1.15	30.40 ± 1.57	30.10 ± 1.47	35.42 ± 1.88	36.39 ± 1.06

Indices	Duration of Exposure							
	2 weeks		4 weeks		3 Months		6 Months	
	Contro l	NiO- NP	Contro l	NiO- NP	Contro l	NiO- NP	Contro l	NiO- NP
A/G index	1.47 ± 0.07	1.46 ± 0.04	1.61 ± 0.06	1.54 ± 0.08	1.38 ± 0.07	1.37 ± 0.12	1.26 ± 0.12	1.22 ± 0.07
ALT activity in blood serum, mM/h-L	68.55 ± 3.67	60.20 ± 4.21	60.88 ± 5.25	76.28 ± 12.56	47.13 ± 2.63	57.61 ± 4.55	76.28 ± 8.03	90.20 ± 5.87
AST activity in blood serum, mM/h-L	225.35 ± 14.31	198.53 ± 9.01	355.63 ± 83.13	444.75 ± 64.77	299.73 ± 14.02	340.77 ± 22.04	265.80 ± 29.09	311.79 ± 29.65
De Ritis coefficient	3.31 ± 0.23	3.33 ± 0.13	5.61 ± 0.92	6.00 ± 0.69	6.43 ± 0.37	6.01 ± 0.32	3.50 ± 0.25	3.50 ± 0.34
SH-groups in blood serum, µmol/L	0.20 ± 0.13	0.35 ± 0.13	0.00 ± 0.00	0.12 ± 0.00	-	-	-	-
Activity of γ- glutamintransferas e in blood serum, nmol/(s-L)	1.68 ± 0.79	0.65 ± 0.14	5.98 ± 1.87	7.75 ± 2.73	0.53 ± 0.34	0.57 ± 0.30	2.62 ± 0.71	2.73 ± 0.69
Alkaline phosphatase in blood serum, nmol/(s-L)	109.38 ± 9.67	120.47 ± 16.71	140.13 ± 6.30	139.62 ± 21.21	119.96 ± 18.69	85.21 ± 11.42	124.15 ± 21.32	113.19 ± 15.08
Lactate dehydrogenase (LDH), U/L	2564.17 ± 244.88	2481.1 7 ± 180.42	2968.33 ± 328.87	3306.6 7 ± 167.41	3691.43 ± 237.78	4010.0 0 ± 162.91	3333.33 ± 250.01	3498.5 7 ± 135.86
Amilase in blood serum, U/L	2730.83 ± 135.12	2685.6 7 ± 80.98	4633.67 ± 384.02	4678.3 3 ± 411.86	3285.57 ± 274.66	3187.0 0 ± 348.41	3339.33 ± 369.49	3378.0 0 ± 227.76
Catalase in blood serum, µmol/L	0.35 ± 0.03	0.38 ± 0.02	0.44 ± 0.04	0.40 ± 0.03	1.90 ± 0.22	2.16 ± 0.11	0.62 ± 0.05	0.60 ± 0.07
Reduced glutathione in the blood hemolysate, µmol/L	30.37 ± 4.78	31.86 ± 8.76	21.54 ± 1.34	22.34 ± 1.68	19.16 ± 1.27	20.04 ± 1.22	21.05 ± 1.66	21.51 ± 1.69
Ceruloplasmin in blood serum, mg/%	54.40 ± 5.26	57.86 ± 5.24	34.25 ± 7.27	31.58 ± 6.21	62.70 ± 12.14	86.37 ± 11.39	68.38 ± 5.18	82.73 ± 7.91
MDA in blood serum, nmol/L	4.36 ± 0.61	4.50 ± 0.60	2.29 ± 0.34	3.19 ± 0.45	3.94 ± 0.15	4.74 ± 0.38	3.85 ± 0.23	4.31 ± 0.43
Uric acid in blood serum, µmol/L	78.00 ± 15.04	92.33 ± 4.18	117.67 ± 15.51	126.83 ± 8.92	133.00 ± 10.37	111.14 ± 12.74	-	-

Indices	Duration of Exposure							
	2 weeks		4 weeks		3 Months		6 Months	
	Contro 1	NiO- NP	Contro 1	NiO- NP	Contro 1	NiO- NP	Contro 1	NiO- NP
Uric acid in urine, µmol/L	55.80 ± 4.15	66.30 ± 16.34	56.83 ± 6.91	64.33 ± 3.11	100.27 ± 12.37	83.92 ± 18.43	-	-
Urea in blood serum, mmol/L	5.38 ± 0.26	5.65 ± 0.49	4.20 ± 0.36	4.88 ± 0.37	2.89 ± 0.66	2.86 ± 0.25	6.43 ± 0.48	6.00 ± 0.41
Urea in urine, mmol/L	121.57 ± 8.10	101.63 ± 10.49	105.84 ± 5.73	117.04 ± 5.32	133.64 ± 8.09	125.97 ± 19.02	81.61 ± 5.36	77.11 ± 4.20
Creatinine in blood serum, µmol/L	39.02 ± 1.89	35.78 ± 1.93	39.02 ± 2.58	38.60 ± 1.44	45.34 ± 2.70	45.50 ± 2.05	45.33 ± 2.15	51.36 ± 2.88
Creatinine in urine, mmol/L	0.69 ± 0.05	0.82 ± 0.15	0.64 ± 0.04	0.72 ± 0.05	1.01 ± 0.09	1.03 ± 0.14	0.97 ± 0.05	0.73 ± 0.03 *
Endogenous creatinine clearance, ml/min	0.72 ± 0.06	0.68 ± 0.06	0.49 ± 0.07	0.42 ± 0.04	0.58 ± 0.11	0.72 ± 0.06	0.87 ± 0.06	0.55 ± 0.11 *
Bilirubin in blood serum, µmol/L	1.02 ± 0.08	1.07 ± 0.13	1.07 ± 0.11	1.32 ± 0.12	1.76 ± 0.18	1.34 ± 0.11	1.97 ± 0.21	1.69 ± 0.12
Cholesterol in blood serum, mmol/L	2.48 ± 0.10	2.31 ± 0.13	2.11 ± 0.16	2.35 ± 0.09	2.15 ± 0.17	2.10 ± 0.12	2.08 ± 0.22	2.48 ± 0.25
High density lipoproteins in blood serum, mmol/L	2.13 ± 0.09	2.00 ± 0.11	1.69 ± 0.09	1.86 ± 0.08	1.87 ± 0.15	1.84 ± 0.13	1.74 ± 0.16	2.07 ± 0.18
Low density lipoproteins in blood serum, mmol/L	0.23 ± 0.02	0.24 ± 0.03	0.21 ± 0.03	0.22 ± 0.02	0.48 ± 0.06	0.42 ± 0.04	0.33 ± 0.05	0.47 ± 0.06
Triglycerides in blood serum, mmol/L	1.10 ± 0.15	0.92 ± 0.05	1.31 ± 0.08	1.38 ± 0.15	0.68 ± 0.03	0.85 ± 0.07 *	0.68 ± 0.10	0.65 ± 0.04
Diuresis, mL	35.80 ± 1.68	31.10 ± 2.05	29.67 ± 3.59	22.29 ± 2.37	25.50 ± 3.80	33.42 ± 2.26	35.25 ± 3.88	40.42 ± 2.34
Urine pH	8.05 ± 0.16	7.65 ± 0.13	7.42 ± 0.08	7.33 ± 0.11	6.91 ± 0.06	7.04 ± 0.07	7.27 ± 0.10	7.04 ± 0.04
Urine relative density, g/mL	1.02 ± 0.00	1.02 ± 0.00	1.01 ± 0.00	1.02 ± 0.00	1.01 ± 0.00	1.02 ± 0.00	1.01 ± 0.00	1.01 ± 0.00
Protein in urine, g/L	47.35 ± 6.79	51.92 ± 14.45	52.47 ± 9.15	52.77 ± 5.83	75.37 ± 7.26	95.03 ± 9.72	-	-

Indices	Duration of Exposure							
	2 weeks		4 weeks		3 Months		6 Months	
	Contro 1	NiO- NP	Contro 1	NiO- NP	Contro 1	NiO- NP	Contro 1	NiO- NP
Total coproporphyrin in urine, μmol	56.93 \pm 9.02	59.56 \pm 7.53	13.91 \pm 5.20	31.23 \pm 8.27	37.76 \pm 10.81	41.38 \pm 7.54	74.83 \pm 20.27	105.26 \pm 33.18
Daily coproporphyrin in urine, μmol	1.70 \pm 0.27	2.25 \pm 0.42	0.36 \pm 0.10	1.50 \pm 0.61	1.46 \pm 0.38	1.46 \pm 0.40	2.07 \pm 0.61	2.92 \pm 0.90
δ -aminolevulinic acid (ALA) in urine, $\mu\text{g/mL}$	15.33 \pm 3.93	15.46 \pm 4.02	-	-	14.04 \pm 3.00	15.02 \pm 5.72	3.94 \pm 1.04	3.39 \pm 0.86
Daily δ -aminolevulinic acid (ALA) in urine, μg	0.49 \pm 0.15	0.55 \pm 0.15	-	-	0.65 \pm 0.17	0.45 \pm 0.15	0.10 \pm 0.03	0.09 \pm 0.02

Note: * statistically significant difference from the control group; $p < 0.05$ by the Student's t-test with Bonferroni correction.

Supplement Table S2. Some cytological characteristics of different organ imprints f; percentage of total cell count ($x \pm \text{s.e.}$)

Organs and cells	Duration of Exposure							
	2 weeks		4 weeks		3 Months		6 Months	
	Control (sham-exposure)	NiO-NP	Control (sham-exposure)	NiO-NP	Control (sham-exposure)	NiO-NP	Control (sham-exposure)	NiO-NP
Lungs								
Neutrophils	6.71 \pm 0.75	7.71 \pm 1.66	6.33 \pm 0.49	8.17 \pm 1.72	10.71 \pm 1.44	8.86 \pm 0.70	6.33 \pm 0.49	6.71 \pm 0.75
Degeneratively changed neutrophils	4.71 \pm 0.92	3.14 \pm 0.40	1.83 \pm 0.31	3.17 \pm 0.48 *	4.71 \pm 0.68	6.43 \pm 0.72	3.50 \pm 0.43	4.71 \pm 0.92
Alveolar macrophages	5.00 \pm 0.93	6.14 \pm 0.59	9.83 \pm 0.75	7.00 \pm 0.97 *	3.43 \pm 0.20	2.86 \pm 0.40	5.00 \pm 0.73	5.00 \pm 0.93
Degeneratively changed alveolar macrophages [®]	6.00 \pm 0.82	17.57 \pm 1.25 *	2.50 \pm 0.56	19.17 \pm 3.03 *	9.14 \pm 1.10	16.14 \pm 2.24 *	10.33 \pm 1.73	6.00 \pm 0.82
Bronchial epithelial cells	18.14 \pm 1.26	7.00 \pm 0.76 *	17.67 \pm 0.88	8.67 \pm 0.49 *	9.14 \pm 1.32	12.86 \pm 1.37	13.83 \pm 1.58	18.14 \pm 1.26

Organs and cells	Duration of Exposure							
	2 weeks		4 weeks		3 Months		6 Months	
	Control (sham-exposure)	NiO-NP	Control (sham-exposure)	NiO-NP	Control (sham-exposure)	NiO-NP	Control (sham-exposure)	NiO-NP
Degeneratively changed bronchial epithelial cells	4.71 ± 0.29	4.29 ± 0.61	3.83 ± 0.48	3.67 ± 0.76	4.00 ± 0.31	9.00 ± 0.87 *	5.67 ± 0.71	4.71 ± 0.29
Lymphocytes	53.43 ± 3.06	53.14 ± 3.52	56.67 ± 1.48	45.50 ± 1.52 *	56.57 ± 2.76	42.00 ± 2.08 *	51.00 ± 3.60	53.43 ± 3.06
Eosinophils	1.29 ± 0.18	1.00 ± 0.22	1.67 ± 0.33	0.83 ± 0.31	2.71 ± 0.57	1.86 ± 0.40	3.33 ± 0.76	1.29 ± 0.18
Lymphatic nodes								
Mature lymphocytes, prolymphocytes	90.33 ± 1.05	87.29 ± 0.99	92.50 ± 0.62	90.80 ± 0.97	88.71 ± 0.99	84.29 ± 0.57 *	89.17 ± 1.01	87.00 ± 1.38
Lymphoblasts	1.50 ± 0.34	1.86 ± 0.40	1.33 ± 0.21	1.20 ± 0.20	1.29 ± 0.18	1.57 ± 0.20	1.33 ± 0.21	1.40 ± 0.24
Reticular cells	0.67 ± 0.21	0.29 ± 0.18	0.00 ± 0.00	0.00 ± 0.00	0.43 ± 0.20	0.71 ± 0.18	0.33 ± 0.21	0.20 ± 0.20
Plasmocytes	2.67 ± 0.42	5.29 ± 0.61 *	1.67 ± 0.49	2.60 ± 0.51	5.29 ± 0.92	5.57 ± 0.48	3.83 ± 0.60	5.20 ± 1.16
Macrophages	1.50 ± 0.34	1.57 ± 0.30	1.50 ± 0.22	2.40 ± 0.24 *	1.71 ± 0.29	3.43 ± 0.30 *	2.00 ± 0.26	2.20 ± 0.20
Neutrophils	2.33 ± 0.76	3.14 ± 0.46	1.83 ± 0.31	2.00 ± 0.77	1.57 ± 0.37	2.71 ± 0.29 *	2.17 ± 0.48	2.40 ± 0.40
Eosinophils	1.00 ± 0.00	0.71 ± 0.18	1.17 ± 0.17	1.00 ± 0.00	1.00 ± 0.22	1.71 ± 0.29	1.17 ± 0.17	1.60 ± 0.40
Spleen								
Mature lymphocytes, prolymphocytes	85.00 ± 0.65	78.29 ± 1.61 *	83.00 ± 0.89	81.67 ± 2.06	70.53 ± 7.58	65.25 ± 7.52	69.37 ± 8.48	63.48 ± 8.59
Lymphoblasts	1.14 ± 0.14	1.71 ± 0.29	1.33 ± 0.42	1.00 ± 0.26	1.01 ± 0.14	1.02 ± 0.16	1.33 ± 0.18	1.16 ± 0.18
Reticular cells	0.29 ± 0.18	0.29 ± 0.18	0.33 ± 0.21	0.33 ± 0.21	0.52 ± 0.14	0.58 ± 0.11	0.52 ± 0.16	0.29 ± 0.12
Plasmocytes	1.29 ± 0.29	1.57 ± 0.37	1.33 ± 0.21	1.33 ± 0.21	3.16 ± 0.58	3.31 ± 0.54	2.51 ± 0.40	3.20 ± 0.62
Macrophages	2.29 ± 0.18	3.14 ± 0.40	1.83 ± 0.31	3.33 ± 0.67	1.72 ± 0.17	2.48 ± 0.31	1.63 ± 0.18	1.70 ± 0.22

Organs and cells	Duration of Exposure							
	2 weeks		4 weeks		3 Months		6 Months	
	Control (sham-exposure)	NiO-NP						
Neutrophils	5.43 ± 0.30	7.00 ± 0.90	7.17 ± 0.79	4.67 ± 1.09	4.67 ± 1.19	6.46 ± 1.85	4.32 ± 0.95	5.87 ± 1.47
Eosinophils	4.57 ± 0.65	8.29 ± 1.57 *	5.00 ± 0.37	7.50 ± 1.18	3.22 ± 0.84	5.10 ± 1.28	3.19 ± 0.81	5.33 ± 1.48
Liver								
Duct epithelial cells	7.00 ± 0.53	9.29 ± 0.57 *	6.83 ± 0.75	7.50 ± 0.76	9.71 ± 1.17	7.71 ± 0.57	9.50 ± 0.72	7.33 ± 0.67
Hepatocytes	69.29 ± 0.64	52.14 ± 3.38 *	66.67 ± 1.28	52.00 ± 4.48 *	59.86 ± 1.64	57.14 ± 3.04	67.67 ± 1.26	58.17 ± 2.47 *
Degeneratively changed hepatocytes®	6.86 ± 0.51	15.71 ± 2.68 *	9.33 ± 1.31	15.33 ± 1.63 *	7.00 ± 1.07	14.00 ± 0.62 *	5.83 ± 0.54	13.17 ± 0.40 *
Neutrophils	4.43 ± 0.48	9.29 ± 1.15 *	5.83 ± 1.14	12.33 ± 1.73 *	12.29 ± 0.99	10.14 ± 1.49	9.00 ± 0.73	9.67 ± 1.17
Eosinophils	6.43 ± 0.69	8.00 ± 0.90	5.33 ± 1.48	7.67 ± 1.52	5.14 ± 0.59	6.43 ± 1.19	3.83 ± 0.31	6.83 ± 1.33
Binucleated hepatocyte	1.43 ± 0.20	1.00 ± 0.00	1.50 ± 0.22	1.17 ± 0.17	1.29 ± 0.18	0.86 ± 0.14	1.33 ± 0.21	1.00 ± 0.00
Kupffer cells	3.29 ± 0.36	4.00 ± 0.53	3.33 ± 0.42	3.33 ± 0.49	3.71 ± 0.61	3.14 ± 0.34	1.83 ± 0.31	3.17 ± 0.17 *
Fibroblasts	1.29 ± 0.18	0.57 ± 0.20 *	1.17 ± 0.31	0.67 ± 0.21	1.14 ± 0.26	0.57 ± 0.20	1.00 ± 0.00	0.67 ± 0.21
Kidney								
Proximal tubule cells	61.57 ± 1.19	51.29 ± 1.69 *	59.17 ± 1.89	48.67 ± 3.44 *	60.00 ± 1.89	59.57 ± 0.72	60.50 ± 1.45	54.33 ± 1.09 *
Degenerated cells of proximal tubules	7.14 ± 0.77	15.14 ± 0.70 *	7.00 ± 0.97	16.67 ± 1.86 *	6.14 ± 1.03	10.14 ± 0.40 *	4.67 ± 0.42	14.83 ± 0.70 *
Distal tubule cells	11.86 ± 1.03	8.57 ± 1.11	12.67 ± 1.12	9.00 ± 1.21	12.86 ± 0.83	7.57 ± 0.53 *	13.17 ± 0.79	7.50 ± 0.62 *
Degenerated cells of distal tubules	5.14 ± 0.40	11.29 ± 0.64 *	4.83 ± 0.48	9.33 ± 0.80 *	4.86 ± 0.40	6.71 ± 0.42 *	4.83 ± 0.48	6.83 ± 0.60 *

Organs and cells	Duration of Exposure							
	2 weeks		4 weeks		3 Months		6 Months	
	Control (sham-exposure)	NiO-NP						
Neutrophils	7.86 ± 0.59	6.71 ± 0.52	7.67 ± 0.61	6.67 ± 0.61	7.57 ± 0.53	6.29 ± 0.64	7.33 ± 0.76	7.33 ± 0.80
Monocytes	4.71 ± 0.57	5.57 ± 0.65	4.67 ± 0.49	6.00 ± 0.58	4.86 ± 0.40	5.14 ± 0.51	6.17 ± 0.48	4.67 ± 0.21 *
Eosinophils	1.29 ± 0.18	1.29 ± 0.18	3.67 ± 0.76	3.50 ± 0.22	3.43 ± 0.61	4.29 ± 0.36	3.00 ± 0.52	4.33 ± 0.49
Fibroblasts	0.43 ± 0.20	0.14 ± 0.14	0.33 ± 0.21	0.17 ± 0.17	0.29 ± 0.18	0.14 ± 0.14	0.33 ± 0.21	0.17 ± 0.17

Note: * statistically significant difference from the control group; p < 0.05 by the Student's t-test with Bonferroni correction.